177946-91-7

Upstream product

• 177948-02-6 4-[(t-butoxycarbonylamino)methyl]-4-hydroxypiperidine 
• 174609-75-7 methanesulfonic acid 3-(5-[1,2,4]triazol-4-yl-1H-indol-3-yl)-propyl ester 
• 177948-00-4 3-(5-[1,2,4-triazol-4-yl]-1H-indol-3-yl)propan-1-ol 
• 23804-68-4 4-(aminomethyl)-1-benzyl-4-hydroxypiperidine 
• 529-20-4 2-methylphenyl aldehyde 
• 177948-04-8 4-Aminomethyl-4-hydroxy-1-[3-[5-(1,2,4-triazol-4-yl)-1H-indol-3-yl]propyl]piperidine 
• 177948-03-7 {4-hydroxy-1-[3-(5-[1,2,4]triazol-4-yl-1H-indol-3-yl)-propyl]-piperidin-4-ylmethyl}-carbamic acid tert-butyl ester 
• 177948-01-5 [[4-hydroxy-1-(phenylmethyl)-4-piperidinyl]methyl]carbamic acid 1,1-dimethylethyl ester 

Relevant academic research and scientific papers

4-hydroxy-1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]piperidines: Selective h5-HT(1D) agonists for the treatment of migraine

A series of 4-hydroxy-l-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl] piperidines was investigated as potential selective h5-HT(1D) agonists for the treatment of migraine. The 4-[(N-benzyl-N-methyl)amino]methyl analog 12a was found to be a full agonist

PALLADIUM CATALYZED INDOLIZATION

We have found that 2-unsubstituted indoles of structural formula (IV) can be cost-effectively synthesized in high yield by the palladium-catalyzed coupling/ring closure of a 2-halo or 2-trifluoromethylsulfonyloxy aniline (I) and an acyl silane derivative (II), followed by deprotection of the silyl protecting groups. The process of the present invention is particularly useful to form indoles containing acid-labile substituents such as triazole, acetyl, ketal, cyano, and carbamate, or indoles having a good leaving group in the benzyl position. The advantages of the present process are that it does not require the use of triphenyl phosphine or tetrabutyl ammonium chloride or lithium chloride. When applied to 5-triazolyl substituted indoles, the present process also eliminates the tendency of triazolyl polymerization in the Fischer indole synthesis. Still further, the present invention is also directed to the novel intermediates of structural formulae (V) and (VI).

Azetidine, pyrrolidine and piperidine derivatives

A class of substituted azetidine, pyrrolidine and piperidine derivatives are selective agonists of 5-HT1 -like receptors, being potent agonists of the human 5-HT1Dα receptor subtype whilst possessing at least a 10-fold selective affinity for the 5-HT1Dα receptor subtype relative to the 5-HT1Dβ subtype; they are therefore useful in the treatment and/or prevention of clinical conditions, in particular migraine and associated disorders, for which a subtype-selective agonist of 5-HT1D receptors is indicated, whilst eliciting fewer side-effects, notably adverse cardiovascular events, than those associated with non-subtype-selective 5-HT1D receptor agonists.